by sfrazee | Aug 14, 2024 | News Article, Uncategorized
By Prof. Casey B. Mulligan and Em. Prof. Tomas J. Philipson Democrats don’t understand healthcare markets. We agree with your editorial “Biden Does a Stealth Medicare Rewrite” (Aug. 6) on the Inflation Reduction Act’s harm to the Medicare drug program. Two years ago,...
by mheinl | Nov 29, 2023 | Uncategorized, White Papers
Expediting breakthrough medical device reimbursement has become a recent public policy issue. This paper provides evidence of the value of faster reimbursement of new medical devices using a comprehensive dataset of past approved devices. The estimation considers the...
by mheinl | Oct 27, 2023 | Uncategorized
By Tomas Philipson October 24, 2023 More than one year ago, President Biden signed the Inflation Reduction Act (IRA) into law. “His top legislative achievement has many flaws. But by far its most damaging effects will be increased illness and death stemming from...
by sfrazee | Nov 1, 2022 | Uncategorized, White Papers
This policy brief contains a set of recommendations for improving access and competition in the state of Wisconsin’s health care system. These recommendations are based on how current state and federal reforms apply to Wisconsin. The brief is focused on four main...
by davidsanders | Dec 8, 2021 | Uncategorized
https://ecchc.economics.uchicago.edu/files/2021/12/2021-12-08-Energy-and-Commerce-Committee-Drug-Innovation_RankingMemberComments_Reference1.mp4 ...
by jmanor | Sep 14, 2021 | Uncategorized, White Papers
This issue brief reviews the evidence on the impact of price controls on biopharmaceutical innovation and calibrates what this evidence implies for recent price control proposals in the US. A large academic literature estimates the effect of future drug revenues on...
